Company intelligence / Profile preview

Laguna Diagnostics

California, United States

Ownership: Private
Development stage: Preclinical

Overview

Laguna Diagnostics has developed a proprietary blood-based molecular biomarker diagnostic platform that uses panels of stable mRNA gene expression signatures to accurately diagnose and differentiate between schizophrenia and bipolar disorder. Their method analyzes the expression levels of 20 specific RNA genes from blood samples, achieving an accuracy of 92%. This approach offers a significant improvement over traditional symptom-based psychiatric diagnosis, which is often slow and error-prone. The technology is positioned as faster ("Days, NOT Years™") and more precise than current standards[2][6].

Therapeutic areas: Psychiatry
Modalities: Molecular diagnostic testRNA-based diagnostic testmRNA gene expression signature panel (diagnostic)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Laguna Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laguna Diagnostics.

Explore the full profile